32.64
-0.07 (-0.21%)
| Previous Close | 32.71 |
| Open | 32.80 |
| Volume | 25,547 |
| Avg. Volume (3M) | 30,532 |
| Market Cap | 285,311,456 |
| Price / Sales | 3.63 |
| Price / Book | 7.36 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Profit Margin | -10.71% |
| Operating Margin (TTM) | -6.22% |
| Diluted EPS (TTM) | -0.990 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Total Debt/Equity (MRQ) | 80.91% |
| Current Ratio (MRQ) | 2.22 |
| Operating Cash Flow (TTM) | -1.80 M |
| Levered Free Cash Flow (TTM) | 1.72 M |
| Return on Assets (TTM) | -5.08% |
| Return on Equity (TTM) | -20.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Sanara MedTech Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.38 |
|
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 66.56% |
| % Held by Institutions | 9.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| World Investment Advisors, Llc | 30 Sep 2024 | 21,112 |
| Salem Investment Counselors Inc | 31 Dec 2024 | 11,215 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 53.19%) | Buy |
| Median | 47.00 (44.00%) | |
| Low | 44.00 (Cantor Fitzgerald, 34.80%) | Buy |
| Average | 47.00 (44.00%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 38.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 23 Jan 2025 | 44.00 (34.80%) | Buy | 38.12 |
| 22 Jan 2025 | 44.00 (34.80%) | Buy | 37.72 | |
| HC Wainwright & Co. | 23 Jan 2025 | 50.00 (53.19%) | Buy | 38.12 |
| 23 Dec 2024 | 50.00 (53.19%) | Buy | 34.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jan 2025 | Announcement | Biomimetic Innovations Ltd, an affiliate of PBC Biomed, Announces an Exclusive License and Distribution Agreement and Minority Investment with Sanara MedTech Inc. |
| 21 Jan 2025 | Announcement | Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd |
| 21 Jan 2025 | Announcement | Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments |
| 21 Jan 2025 | Announcement | Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 |
| 25 Nov 2024 | Announcement | Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th |
| 12 Nov 2024 | Announcement | Sanara MedTech Inc. Reports Third Quarter 2024 Results |
| 31 Oct 2024 | Announcement | Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |